Future Medicine Co., Ltd.

2:30 PM - 2:45 PM (PDT), Tuesday, June 14, 2022
Future Medicine is a clinical-stage Korean biotech company mainly developing small molecules that have promising drug profiles in three different disease areas

1) Inflammation/Fibrosis
Our leading program, FM101, is an anti-inflammatory/Fibrotic agent that targets the A3AR pathway.
FM101 is in phase 2 clinical trial with the indications of Non-alcoholic steatohepatitis and Glaucoma.
Also, FM101 has shown potential to address unmet needs of renal inflammation and fibrosis in preclinical Proof of concept.

2) Cancer
The complexity of tumor biology has driven serious medical unmet needs in various tumor patients.
Our strategy of oncology program development aims to solve unmet medical needs by implementing multifaceted approaches such as Immune (A2AAR), Metabolism (MDH1/2), Targeted (IRAK4/PIM1), and Mitotic (GSG2) driven-tumor pathway

3) Autoimmune disease
Rheumatoid arthritis is our indication of interest. We have a competitive IRAK4 program that is preclinical-ready.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Non alcoholic steatohepatitis, Glaucoma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Team Manager
Future Medicine Co., Ltd.